Zobrazeno 1 - 10
of 1 758
pro vyhledávání: '"M, Suga"'
Autor:
Song Yao, Shipra Gandhi, Christine B Ambrosone, Warren Davis, Eva Culakova, Guilherme Cantuaria, Lori Sakoda, Igor PuzanovCI, Michelle Janelsins, Thaer Khoury, Elisa Rodriguez, Allison Magnuson, Jennifer M Suga, Rajasree P Chowdry, Lawrence H Kushi, Karen Mustian, Gary R Morrow, Charles Kamen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/fbc6be5bb2b849b5be946d1a17fe9b4c
Autor:
Charles E. Geyer, Jr, Gong Tang, Priya Rastogi, Vicente Valero, Stephen K. Chia, Erin F. Cobain, Elias Obeid, David B. Page, Andrew S. Poklepovic, William J. Irvin, Jr., Adam M. Brufsky, Irene L. Wapnir, Jennifer M. Suga, Eleftherios (Terry) Mamounas, Norman Wolmark
Publikováno v:
Cancer Research. 83:OT2-16
Background: The CLEOPATRA trial established trastuzumab, pertuzumab and a taxane (THP) as a standard of care for first line metastatic, HER2-positve breast cancer with median progression-free survival (PFS) of 18.7 months and median OS of 57 months.
Autor:
Senthil, Damodaran, Fengmin, Zhao, Dustin A, Deming, Edith P, Mitchell, John J, Wright, Robert J, Gray, Victoria, Wang, Lisa M, McShane, Larry V, Rubinstein, David R, Patton, P Mickey, Williams, Stanley R, Hamilton, Jennifer M, Suga, Barbara A, Conley, Carlos L, Arteaga, Lyndsay N, Harris, Peter J, O'Dwyer, Alice P, Chen, Keith T, Flaherty
Publikováno v:
J Clin Oncol
Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies on the basis of matching genomic alterations. Arm Z1F evaluated copanlisib,
Autor:
Senthil Damodaran, Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John J. Wright, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Jennifer M. Suga, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Publikováno v:
Journal of Clinical Oncology. 40:1552-1561
PURPOSE Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies on the basis of matching genomic alterations. Arm Z1F evaluated cop
Autor:
Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, Jennifer M. Suga, Marcus S. Noel, Jordan Berlin, Michael J. Pishvaian, Florencia Jalikis, Elizabeth M. Swisher, Philip A. Philip, Katherine A. Guthrie, E. Gabriela Chiorean
Protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50a4d2e0c0f632703c894986b60a2ec8
https://doi.org/10.1158/1078-0432.22483598.v1
https://doi.org/10.1158/1078-0432.22483598.v1
Autor:
Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, Jennifer M. Suga, Marcus S. Noel, Jordan Berlin, Michael J. Pishvaian, Florencia Jalikis, Elizabeth M. Swisher, Philip A. Philip, Katherine A. Guthrie, E. Gabriela Chiorean
Table S1: BROCA-HR gene list Table S2: Best Response, TTP, OS in Patients with HR-DDR Defects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aa7244ad887ba1c96708f23ce42ce3e
https://doi.org/10.1158/1078-0432.22483595
https://doi.org/10.1158/1078-0432.22483595
Autor:
Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, Jennifer M. Suga, Marcus S. Noel, Jordan Berlin, Michael J. Pishvaian, Florencia Jalikis, Elizabeth M. Swisher, Philip A. Philip, Katherine A. Guthrie, E. Gabriela Chiorean
Purpose:PARP inhibitors synergize with topoisomerase inhibitors, and veliparib plus modified (m) FOLFIRI (no 5-FU bolus) had preliminary activity in metastatic pancreatic cancers. This study evaluated the safety and efficacy of second-line treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29e14e2256fbd8da39e6b01f4ebec903
https://doi.org/10.1158/1078-0432.c.6531176.v1
https://doi.org/10.1158/1078-0432.c.6531176.v1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michael, Gnant, Amylou C, Dueck, Sophie, Frantal, Miguel, Martin, Hal J, Burstein, Richard, Greil, Peter, Fox, Antonio C, Wolff, Arlene, Chan, Eric P, Winer, Georg, Pfeiler, Kathy D, Miller, Marco, Colleoni, Jennifer M, Suga, Gabor, Rubovsky, Judith M, Bliss, Ingrid A, Mayer, Christian F, Singer, Zbigniew, Nowecki, Olwen, Hahn, Jacqui, Thomson, Norman, Wolmark, Kepa, Amillano, Hope S, Rugo, Guenther G, Steger, Blanca, Hernando Fernández de Aránguiz, Tufia C, Haddad, Antonia, Perelló, Meritxell, Bellet, Hannes, Fohler, Otto, Metzger Filho, Anita, Jallitsch-Halper, Kadine, Solomon, Céline, Schurmans, Kathy P, Theall, Dongrui R, Lu, Kathleen, Tenner, Christian, Fesl, Angela, DeMichele, Erica L, Mayer
Publikováno v:
Journal of Clinical Oncology. 40:282-293
PURPOSE Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor–positive breast cancer has not been
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.